Literature DB >> 7724101

Prognostic significance of human papillomavirus DNA in vulvar carcinoma.

B J Monk1, R A Burger, F Lin, G Parham, S A Vasilev, S P Wilczynski.   

Abstract

OBJECTIVE: To determine the histopathologic, epidemiologic, and prognostic significance of human papillomavirus (HPV) DNA in primary invasive vulvar cancer.
METHODS: From December 1981 through October 1992, primary tumor tissue from 55 newly diagnosed vulvar cancers was evaluated for the presence of HPV DNA. The DNA was extracted from tumor tissue and subjected to the polymerase chain reaction (PCR) using highly conserved consensus L1 primers that detect 25 different HPV genotypes and primers specific for HPV type 6/E6, type 16/E7, and type 18/E6 gene sequences. All PCR products were hybridized to type-specific radiolabeled probes. The association between the presence of HPV DNA and histologic, epidemiologic, and clinical characteristics was analyzed.
RESULTS: Thirty-three (60%) tumors contained HPV DNA. Patients younger than 70 years of age or who smoked were more likely to have HPV-positive vulvar cancers. Twenty-one (95%) of 22 tumors classified as basaloid, warty, or verrucous contained HPV DNA, whereas 12 (39%) of 31 typical squamous tumors contained HPV (P < .001). Two adenocarcinomas were negative for HPV. Tumors with or without HPV DNA did not differ with respect to International Federation of Obstetricians and Gynecologists stage (size and nodal status), tumor grade, or therapy. Using life-table analysis, the absence of HPV DNA and the presence of regional nodal metastasis were predictive of recurrence and death from vulvar cancer. When controlling for lesion size, age, tumor grade, and nodal metastasis using the Cox proportional hazards model, only HPV status remained an independent prognostic factor.
CONCLUSION: Human papillomavirus DNA is more common in vulvar cancers of young women who smoke than in older nonsmokers. Patients with HPV-negative tumors are at an increased risk of recurrence and death from vulvar cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7724101     DOI: 10.1016/0029-7844(95)00045-s

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  22 in total

1.  A fibromyxoid stromal response is associated with an infiltrative tumor morphology, perineural invasion, and lymph node metastasis in squamous cell carcinoma of the vulva.

Authors:  Susanne K Jeffus; Ashita Gehlot; Emily Holthoff; Rebecca Stone; Horace Spencer; Thomas Kelly; Steven R Post; Charles M Quick
Journal:  Am J Surg Pathol       Date:  2015-09       Impact factor: 6.394

2.  Diagnosis, Therapy and Follow-up Care of Vulvar Cancer and its Precursors. Guideline of the DGGG and DKG (S2k-Level, AWMF Registry Number 015/059, November 2015.

Authors:  H G Schnürch; S Ackermann; C D Alt; J Barinoff; C Böing; C Dannecker; F Gieseking; A Günthert; P Hantschmann; L C Horn; R Kürzl; P Mallmann; S Marnitz; G Mehlhorn; C C Hack; M C Koch; U Torsten; W Weikel; L Wölber; M Hampl
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-10       Impact factor: 2.915

3.  Detection of human papillomavirus in vulval carcinoma using semi-nested PCR and restriction enzyme typing: a rapid and sensitive technique.

Authors:  N H Cartwright; L J Cassia; A J Easton; A G Morris
Journal:  Clin Mol Pathol       Date:  1996-08

4.  An AP-1 binding site mutation in HPV-16 LCR enhances E6/E7 promoter activity in human oral epithelial cells.

Authors:  Yanna Liu; Jun Z Li; Xiao H Yuan; Karen Adler-Storthz; Zhuo Che
Journal:  Virus Genes       Date:  2002       Impact factor: 2.332

5.  Prevalence of human papillomavirus types in invasive vulvar cancers and vulvar intraepithelial neoplasia 3 in the United States before vaccine introduction.

Authors:  Julia W Gargano; Edward J Wilkinson; Elizabeth R Unger; Martin Steinau; Meg Watson; Youjie Huang; Glenn Copeland; Wendy Cozen; Marc T Goodman; Claudia Hopenhayn; Charles F Lynch; Brenda Y Hernandez; Edward S Peters; Maria Sibug Saber; Christopher W Lyu; Lauren A Sands; Mona Saraiya
Journal:  J Low Genit Tract Dis       Date:  2012-10       Impact factor: 1.925

6.  Tumor proteomics by multivariate analysis on individual pathway data for characterization of vulvar cancer phenotypes.

Authors:  Annsofi Sandberg; Gunnel Lindell; Brita Nordström Källström; Rui Mamede Branca; Kristina Gemzell Danielsson; Mats Dahlberg; Barbro Larson; Jenny Forshed; Janne Lehtiö
Journal:  Mol Cell Proteomics       Date:  2012-04-12       Impact factor: 5.911

7.  Human papillomavirus-related gynecologic neoplasms: screening and prevention.

Authors:  Whitfield B Growdon; Marcela Del Carmen
Journal:  Rev Obstet Gynecol       Date:  2008

Review 8.  HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women.

Authors:  Maura L Gillison; Anil K Chaturvedi; Douglas R Lowy
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

Review 9.  A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States.

Authors:  Ralph P Insinga; Kai-Li Liaw; Lisa G Johnson; Margaret M Madeleine
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-07       Impact factor: 4.254

10.  Human papillomavirus genotyping and e6/e7 mRNA expression in greek women with intraepithelial neoplasia and squamous cell carcinoma of the vagina and vulva.

Authors:  Elpida Tsimplaki; Elena Argyri; Lina Michala; Maria Kouvousi; Aikaterini Apostolaki; George Magiakos; Issidora Papassideri; Efstathia Panotopoulou
Journal:  J Oncol       Date:  2011-12-05       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.